Cell Biology Laboratory, Jilin Province Institute of Cancer Prevention and Treatment, Jilin Cancer Hospital, Changchun 130012, China.
Department of Internal Medicine, Southern Branch of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 102600, China.
J Zhejiang Univ Sci B. 2020;21(3):179-191. doi: 10.1631/jzus.B1900312.
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases. The pathogenesis of NSCLC involves complex gene networks that include different types of non-coding RNAs, such as long non-coding RNAs (lncRNAs). The role of lncRNAs in NSCLC is gaining an increasing interest as their function is being explored in various human cancers. Recently, a new oncogenic lncRNA, LINC00152 (cytoskeleton regulator RNA (CYTOR)), has been identified in different tumor types. In NSCLC, the high expression of LINC00152 in tumor tissue and peripheral blood samples has been shown to be associated with worse prognoses of NSCLC patients. Overexpression of LINC00152 has been confirmed to promote the proliferation, invasion, and migration of NSCLC cells in vitro, as well as increase tumor growth in vivo. This review discusses the role of LINC00152 in NSCLC.
非小细胞肺癌(NSCLC)约占所有肺癌病例的 85%。NSCLC 的发病机制涉及复杂的基因网络,包括不同类型的非编码 RNA,如长非编码 RNA(lncRNA)。随着人们对各种人类癌症中 lncRNA 功能的探索,lncRNA 在 NSCLC 中的作用越来越受到关注。最近,在不同的肿瘤类型中发现了一种新的致癌 lncRNA,LINC00152(细胞骨架调节 RNA(CYTOR))。在 NSCLC 中,肿瘤组织和外周血样本中 LINC00152 的高表达与 NSCLC 患者的预后不良相关。过表达 LINC00152 已被证实可促进 NSCLC 细胞在体外的增殖、侵袭和迁移,并增加体内肿瘤生长。本综述讨论了 LINC00152 在 NSCLC 中的作用。